Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female adults \>/= 18 years of age (from the 18th birthday) at enrollment and older.~2. Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.~3. Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.~Exclusion Criteria:~1. Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.~2. History of microbiologically proven invasive disease caused by S pneumoniae.~3. Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.~4. Pregnant female subjects or breastfeeding female subjects.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 60 years and above 20vPnC/Saline (Type: EXPERIMENTAL): 20vPnC and saline
- 60 years and above 13vPnC/PPSV23 (Type: ACTIVE_COMPARATOR): 13vPnC and PPSV23
- 50 through 59 years of age 20vPnC (Type: EXPERIMENTAL): 20vPnC
- 18 through 49 years of age 20vPnC (Type: EXPERIMENTAL): 20vPnC
- 50 through 59 years of age 13vPnC (Type: ACTIVE_COMPARATOR): 13vPnC
- 18 through 49 years of age 13vPnC (Type: ACTIVE_COMPARATOR): 13vPnC

Based on this trial design, predict the completion outcome and termination type (if applicable).